经导管主动脉瓣治疗结局的性别差异:2011年至2014年TVT注册研究
基于美国胸外科医师学会/美国心脏病学会经导管瓣膜治疗注册研究,2011年至2014年共纳入11808例(49.9%)女性和11844例(51.1%)男性经导管主动脉瓣置换术患者。女性住院血管并发症高于男性(8.27% vs 4.39%;校正HR 1.70;95%CI 1.34-2.14;p<0.001),但1年死亡率低于男性(21.3% vs 24.5%;校正HR 0.73;95%CI 0.63-0.85;p<0.001)。
要点
- 女性TAVR患者较男性年龄更大、STS评分更高(9.0% vs 8.0%),非股动脉入路更多(45.0% vs 34.0%)。
- 女性住院血管并发症高于男性(8.27% vs 4.39%;校正HR 1.70;95%CI 1.34-2.14;p<0.001)。
- 女性1年死亡率低于男性(21.3% vs 24.5%;校正HR 0.73;95%CI 0.63-0.85;p<0.001)。
核心结论
- 尽管女性TAVR后住院血管并发症的校正风险更高,但女性1年校正生存优于男性。
研究设计与样本
- 使用美国胸外科医师学会/美国心脏病学会经导管瓣膜治疗注册研究的全国数据评估住院结局,并链接美国医疗保险和医疗补助服务中心数据提供1年事件。
- 2011年至2014年共11808例(49.9%)女性和11844例(51.1%)男性接受TAVR。
- 住院结局采用多变量逻辑回归校正,非致命性1年结局采用Fine-Gray模型考虑死亡竞争风险。
主要发现
- 女性较男性年龄更大,冠状动脉疾病、心房颤动和糖尿病患病率更低,但瓷样主动脉比例更高、肾小球滤过率更低、平均STS评分更高(9.0% vs 8.0%;所有p<0.001)。
- 女性较男性更常采用非股动脉入路(45.0% vs 34.0%)。
- 尽管使用更小的器械尺寸,女性达到瓣膜覆盖指数≥8%的比例高于男性(66% vs 54%)。
- 女性住院血管并发症高于男性(8.27% vs 4.39%;校正HR 1.70;95%CI 1.34-2.14;p<0.001),出血有升高趋势(8.01% vs 5.96%;校正HR 1.19;95%CI 0.99-1.44;p=0.06)。
- 女性1年死亡率低于男性(21.3% vs 24.5%;校正HR 0.73;95%CI 0.63-0.85;p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A differential impact of sex has been observed in transcatheter aortic valve replacement (TAVR) outcomes from small observational studies and subgroup analyses of randomized trials. OBJECTIVES: The goal of this study was to compare the in-hospital and 1-year outcomes in male and female subjects from the U.S. nationwide TAVR registry. METHODS: National data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry were used for in-hospital outcomes, and data linked from the Centers for Medicare & Medicaid Services were used to provide 1-year events. Multivariable logistic regression adjustment was performed for in-hospital outcomes. Fine-Gray models were used for nonfatal 1-year outcomes to account for the competing risk of death. RESULTS: From 2011 to 2014, a total of 11,808 (49.9%) women and 11,844 (51.1%) men underwent TAVR. Compared with male patients, female patients were older, with a lower prevalence of coronary artery disease, atrial fibrillation, and diabetes but a higher rate of porcelain aorta, lower glomerular filtration rate, and higher mean Society of Thoracic Surgeons score (9.0% vs. 8.0%; all p < 0.001). Women were treated more often by using nontransfemoral access than men (45.0% vs. 34.0%). Despite using smaller device sizes, women achieved valve cover index ≥8% more often than men (66% vs. 54%). In-hospital vascular complications were higher in women (8.27% vs. 4.39%; adjusted hazard ratio [HR]: 1.70; 95% CI: 1.34 to 2.14; p < 0.001) and a trend toward higher bleeding (8.01% vs 5.96%; adjusted HR: 1.19; 95% CI: 0.99 to 1.44; p = 0.06) was observed; however, 1-year mortality was lower (21.3% vs. 24.5%; adjusted HR: 0.73; 95% CI: 0.63 to 0.85; p < 0.001) in women than in men. CONCLUSIONS: Female patients undergoing TAVR had a different risk profile compared with male patients. Notwithstanding a greater adjusted risk for in-hospital vascular complications, 1-year adjusted survival was superior in female patients.
引用
- Chandrasekhar J, Dangas G, Yu J, et al. Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy: TVT Registry From 2011 to 2014. J Am Coll Cardiol. 2016. PMID: 28007135. doi:10.1016/j.jacc.2016.10.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。